Warren M Kati Selected Research

Human Influenza (Influenza)

3/2008	Synthesis of potent pyrrolidine influenza neuraminidase inhibitors.
6/2005	Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors.
1/2005	Design, synthesis, and structural analysis of inhibitors of influenza neuraminidase containing a 2,3-disubstituted tetrahydrofuran-5-carboxylic acid core.
4/2002	In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Warren M Kati Research Topics

Disease

9	Neoplasms (Cancer) 01/2023 - 01/2017
6	Infections 01/2022 - 04/2002
4	Human Influenza (Influenza) 03/2008 - 04/2002
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 07/2022 - 01/2017
2	Prostatic Neoplasms (Prostate Cancer) 10/2021 - 01/2020
2	Hepatitis C 03/2011 - 01/2004
1	Primary Myelofibrosis (Myelosclerosis) 07/2022
1	COVID-19 01/2022
1	Breakthrough Infections 01/2022
1	Virus Diseases (Viral Diseases) 01/2021
1	Inflammation (Inflammations) 10/2017
1	Carcinogenesis 01/2017
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2017
1	Multiple Myeloma 01/2017
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2017
1	Hematologic Neoplasms (Hematological Malignancy) 01/2017
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2017
1	Hyperbilirubinemia 04/2009

Drug/Important Bio-Agent (IBA)

6	mivebresibIBA 07/2022 - 01/2017
5	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2017
4	EnzymesIBA 01/2022 - 04/2002
3	Antiviral Agents (Antivirals)IBA 01/2022 - 01/2018
3	Neuraminidase (Sialidase)IBA 03/2008 - 01/2005
2	Peptide Hydrolases (Proteases)FDA Link 01/2022 - 01/2004
2	ABBV-744IBA 10/2021 - 01/2020
2	pyrrolidineIBA 03/2008 - 06/2005
1	Phospholipid Hydroperoxide Glutathione PeroxidaseIBA 01/2023
1	PapainIBA 01/2022
1	nirmatrelvir and ritonavir drug combinationIBA 01/2022
1	remdesivirIBA 01/2022
1	Neutralizing AntibodiesIBA 01/2022
1	COVID-19 VaccinesIBA 01/2022
1	VaccinesIBA 01/2022
1	RNA-Dependent RNA Polymerase (RNA Dependent RNA Polymerase)IBA 01/2022
1	Androgen Receptors (Androgen Receptor)IBA 10/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	AndrogensIBA 01/2020
1	Viekira PakIBA 10/2018
1	ombitasvirIBA 10/2018
1	NucleosidesIBA 01/2018
1	ABT-072IBA 01/2018
1	Bromodomain Containing ProteinsIBA 11/2017
1	venetoclaxIBA 01/2017
1	quinolineIBA 03/2011
1	BilirubinIBA 04/2009
1	AcidsIBA 01/2005
1	tetrahydrofuranIBA 01/2005
1	Carboxylic AcidsIBA 01/2005
1	Zanamivir (Relenza)FDA Link 04/2002
1	peramivirIBA 04/2002
1	A 315675IBA 04/2002
1	oseltamivir carboxylateIBA 04/2002
1	Oseltamivir (Tamiflu)FDA Link 04/2002

Therapy/Procedure

5	Therapeutics 01/2023 - 04/2002
1	Duration of Therapy 10/2018